Scarica l'app Stockscreener
60.27
2.16%
-1.33
Dopo l'orario di chiusura:
60.04
-0.23
-0.38%
Precedente Chiudi:
$61.60
Aprire:
$61.1
Volume 24 ore:
5.89M
Relative Volume:
0.92
Capitalizzazione di mercato:
$10.82B
Reddito:
$1.36B
Utile/perdita netta:
$-302.91M
Rapporto P/E:
-35.08
EPS:
-1.7182
Flusso di cassa netto:
$-219.93M
1 W Prestazione:
+9.84%
1M Prestazione:
+21.46%
6M Prestazione:
-3.35%
1 anno Prestazione:
+1.84%
Intervallo 1D:
$58.91
$63.10
Intervallo di 1 settimana:
$53.37
$63.11
Portata 52W:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Nome
Tempus Ai Inc
Settore
Industria
Telefono
800-976-5448
Indirizzo
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
60.27 | 10.40B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
192.74 | 28.83B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
69.03 | 13.69B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
95.31 | 7.55B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
84.05 | 6.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Jefferies | Underperform |
| 2026-04-13 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-02-19 | Iniziato | Mizuho | Outperform |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-21 | Downgrade | TD Cowen | Buy → Hold |
| 2025-10-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-09-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-21 | Iniziato | BTIG Research | Buy |
| 2025-02-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Ripresa | TD Cowen | Buy |
| 2024-12-13 | Iniziato | Wolfe Research | Outperform |
| 2024-12-09 | Iniziato | Guggenheim | Buy |
| 2024-11-11 | Downgrade | Stifel | Buy → Hold |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-08-12 | Iniziato | Piper Sandler | Neutral |
| 2024-07-09 | Iniziato | BofA Securities | Buy |
| 2024-07-09 | Iniziato | JP Morgan | Overweight |
| 2024-07-09 | Iniziato | Longbow | Buy |
| 2024-07-09 | Iniziato | Loop Capital | Buy |
| 2024-07-09 | Iniziato | Morgan Stanley | Overweight |
| 2024-07-09 | Iniziato | Needham | Buy |
| 2024-07-09 | Iniziato | Stifel | Buy |
| 2024-07-09 | Iniziato | TD Cowen | Buy |
| 2024-07-09 | Iniziato | William Blair | Outperform |
Mostra tutto
Tempus Ai Inc Borsa (TEM) Ultime notizie
Tempus AI (NASDAQ:TEM) Stock Rating Upgraded by Freedom Capital - MarketBeat
TEM Stock Slips Overnight: CEO-Linked $9.6M Share Sale Puts A Cloud Over 'AI As Physician' Story - Stocktwits
Tempus AI(TEM.US) 10% Shareholder Sells US$9.56 Million in Common Stock - Moomoo
CEO Eric Lefkofsky entities sell 166,250 Tempus AI (TEM) shares under 10b5-1 plan - Stock Titan
TEM Initiated Coverage by Freedom Capital Markets -- Rating Set to Hold - GuruFocus
Tempus AI (TEM) Holds Steady Near Support Amid Modest PullbackDollar Neutral Pair - dars.gov.et
Does Tempus AI’s (TEM) xH Launch Quietly Redraw Its Long‑Term Data Moat Strategy? - simplywall.st
Correction: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI - Yahoo Finance
Correction: Biovica refocuses US commercial strategy and terminates agreement with Tempus AI - TradingView
Biovica Refocuses US Commercial Strategy, Terminates Deal With Tempus AI - TradingView
Biovica refocuses US commercial strategy and terminates agreement with Tempus AI - marketscreener.com
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion (NASDAQ:TEM) - Seeking Alpha
Form 4 Tempus AI Inc For: 29 June By Investing.com - Investing.com Canada
Tempus AI CFO James Rogers sells $634,095 in TEM stock - Investing.com UK
Tempus AI CFO James Rogers sells $634,095 in TEM stock By Investing.com - Investing.com Australia
Tempus AI director Jennifer Doudna sells $147,015 in stock By Investing.com - Investing.com Nigeria
Tempus AI (TEM) director sells 2,673 shares under 10b5-1 plan - Stock Titan
Form 144 Tempus AI For: 29 June By Investing.com - Investing.com South Africa
$Tempus AI (TEM.US)$ whats next …. - Moomoo
Tempus AI (NASDAQ: TEM) insiders report multi-holder Class A sales - Stock Titan
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback - Barchart.com
Tempus AI, Inc. (TEM) Stock Analysis: Growth Prospects Amidst a Complex Financial Landscape - DirectorsTalk Interviews
Tempus AI (TEM) is Amongst AI stocks Under $30 That Carry High Short Interest - Insider Monkey
Tempus AI (TEM) Expands Rare Cancer Research, Is The Stock Fully Priced? - simplywall.st
5 Worst Artificial Intelligence Stocks Under $30 According to Short Sellers - Insider Monkey
How genetic testing company Tempus AI is using data and artificial intelligence to help personalize cancer care - MSN
Tempus AI Stock (TEM) Opinions on Healthcare AI Breakthroughs - Quiver Quantitative
Tempus AI Stock Short Interest Rises to 38.44% - Quiver Quantitative
Tempus AI, Inc. $TEM Shares Sold by SG Americas Securities LLC - MarketBeat
Tempus AI stock jumps on rare cancer research partnership - Investing.com
How Genetic Testing Company Tempus AI Is Using Data and Artificial Intelligence to Help Personalize Cancer Care - SurvivorNet
Why is Tempus AI stock rallying today? - Investing.com UK
TEM (NASDAQ: TEM) insider resale: 11,529 RSU shares listed for sale - Stock Titan
Why is Tempus AI stock rallying today? By Investing.com - Investing.com Nigeria
Investors Purchase High Volume of Call Options on Tempus AI (NASDAQ:TEM) - MarketBeat
Tempus AI, Inc. Class A Actuals & Estimates (NASDAQ:TEM) - TradingView
Tempus AI partners with Angiosarcoma Awareness on rare cancer research By Investing.com - Investing.com South Africa
Tempus AI stock jumps on rare cancer research partnership By Investing.com - Investing.com Nigeria
Tempus AI partners with Angiosarcoma Awareness on rare cancer research - Investing.com
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers - marketscreener.com
TEM Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
Price to sales forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
Price to book forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
Enterprise value to EBIT forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
Enterprise value to revenue forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
Price to earnings forward of Tempus AI, Inc. – NASDAQ:TEM - TradingView
The pink kinda moving average line is a little problem, the red dashed is certainly a take profit and wait line - Moomoo
Is Tempus AI, Inc. (TEM) Among the Best AI Drug Discovery Stocks to Buy According to Hedge Funds? - Insider Monkey
Tempus Ai Inc Azioni (TEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tempus Ai Inc Azioni (TEM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Doudna Jennifer A | Director |
Jun 25 '26 |
Sale |
55.00 |
2,673 |
147,015 |
25,942 |
| Rogers James William | Chief Financial Officer |
Jun 25 '26 |
Sale |
55.00 |
11,529 |
634,095 |
114,866 |
1.17%
3.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):